METROPOLIS Share Price Performance
₹0
-495.40 (-100.00%)
Price ₹0
Fair Value₹508.64
Share Pricen/a
Narrative Update • Jul 15
Metropolis Healthcare Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
METROPOLIS Community Narratives
AN
Fair Value
·Fair Value ₹508.64 12.1% overvalued intrinsic discount
Digital Testing Will Undermine Traditional Diagnostics Profitability
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value ₹715 20.3% undervalued intrinsic discount
India's Rising Healthcare And Digital Adoption Will Expand Diagnostic Reach
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value ₹608.6 6.3% undervalued intrinsic discount
Rural Market Expansion And Digitalization Will Transform Diagnostics
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Digital Testing Will Undermine Traditional Diagnostics Profitability
At-home test kits and other digital health tools are starting to chip away at the traditional lab-testing business, and that could squeeze Metropolis Healthcare’s pricing and growth. The key question is whether its push into higher-value specialty testing, smarter operations, and selective deals can stay ahead of tougher competition and tighter rules.Read more
AN
₹508.64
12.1% overvalued intrinsic discount
Fair Value
Revenue
13.26% p.a.
Profit Margin
16.43%
Future PE
38x
Price in 2029
₹723.9
Rural Market Expansion And Digitalization Will Transform Diagnostics
Metropolis Healthcare is pushing deeper into smaller cities and rural areas while nudging customers toward higher-end tests, which could lift demand and improve the quality of its sales. The big question is whether it can keep prices and service levels strong as it buys other labs and faces tougher competition in specialized testing.Read more
AN
₹608.6
6.3% undervalued intrinsic discount
Fair Value
Revenue
13.93% p.a.
Profit Margin
15.78%
Future PE
46.5x
Price in 2029
₹866.16
India's Rising Healthcare And Digital Adoption Will Expand Diagnostic Reach
Metropolis Healthcare looks set to grow faster than many expect as it folds in recent deals, expands its sample pickup network, and uses digital tools to reach patients beyond big cities. But the story depends on staying ahead of tougher rivals and rule changes, while new ways of testing at home and a heavy reliance on a few regions could pressure growth and pricing.Read more
AN
₹715
20.3% undervalued intrinsic discount
Fair Value
Revenue
15.78% p.a.
Profit Margin
16.21%
Future PE
50.66x
Price in 2029
₹1.02k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
METROPOLIS: Aggressive Diagnostics Expansion And Acquisitions Will Likely Pressure Future Returns
Fair Value: ₹508.64 12.1% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
METROPOLIS: Future Expansion Will Rely On Acquisitions In Diagnostics
Fair Value: ₹608.6 6.3% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
METROPOLIS: Genomics And Specialty Diagnostics Expansion Will Drive Future Upside
Fair Value: ₹715 20.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Metropolis Healthcare Limited Key Details
About METROPOLIS
- Founded
- 1980
- Employees
- 4823
- CEO
- WebsiteView website
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.
Recent METROPOLIS News & Updates
Narrative Update • Jul 01
METROPOLIS: Future Expansion Will Rely On Acquisitions In Diagnostics
Metropolis Healthcare's analyst fair value estimate has been revised from approximately ₹2,144.53 to ₹608.60. Analysts point to slightly adjusted assumptions for revenue growth, profit margins, and future P/E as the key drivers of this change.
Narrative Update • Jun 17
